- Professor of Psychiatry
- Director, Yale Depression Research Program
- Co-Director, Yale New Haven Hospital Interventional Psychiatry Service
Depression, psychopharmacology and brain stimulation modalities (ECT and TMS), mood disorders, anxiety, suicide
My work is concentrated largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders. Much of my recent research has focused on identifying the contributions of the amino acid neurotransmitter systems (GABA and Glutamate) to the neurobiology of mood disorders and the mechanism of antidepressant action. Specifically, my basic science laboratory employs rodent models to explore the effects of chronic stress on cellular and molecular biology, and examines the molecular, cellular and behavioral effects of novel treatment strategies targeting these affected systems. My clinical laboratory employs novel magnetic resonance spectroscopy methodologies and pharmacological challenge paradigms to identify abnormalities in the function of the amino acid neurotransmitter systems in individuals suffering from mood and anxiety disorders.
Psychiatrist Dr. Gerard Sanacora on potential side effects when using ketamine to treat depression
The New York Times
Dr. Gerard Sanacora on a new ketamine-related depression drug recommended by FDA panel
NBC News
Ketamine for severe depression: ‘How do you not offer this drug to people?’
NPR
The dangers of using the club drug ketamine for depression
TIME